US4652548A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
Assignee: Eli Lilly and Co
•
Filing: 1984-12-17
•
Granted: 1987-03-24
•
Expires: 2004-12-17
Abstract
Abstract A pharmaceutical composition which comprises, in association with a pharmaceutically acceptable carrier, human insulin, human C-peptide, and human proinsulin, said human C-peptide being present in a molar ratio, human insulin to human C-peptide, of from about 1:4 to about 4:1, and said human proinsulin being present in a weight ratio, human insulin to human proinsulin, of from about 1:100 to about 100:1, is useful in treating diabetics and in promoting attainment of natural hormonal homeostasis, thereby preventing or substantially diminishing or retarding diabetic complications.
Inventors
- 👤 Ronald E. Chance
- 👤 Bruce H. Frank
- 👤 John A. Galloway
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:35
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/28
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
85 words
A method for more nearly achieving and maintaining natural hormonal homeostasis in a diabetic state, which comprises administering, in association with a pharmaceutically acceptable carrier, pharmaceutically acceptable amounts of human insulin, human C-peptide, and human proinsulin, said human C-peptide being present in a ratio on a molar basis, human insulin to human C-peptide, of from about 1:4 to about 4:1, and said human proinsulin being present in a ratio on a weight basis, human insulin to human proinsulin, of from about 1:100 to about 100:1.
Claim 2
Independent Claim
85 words
A method for more nearly achieving and maintaining natural hormonal homeostasis in a diabetic state, which comprises administering, in association with a pharmaceutically acceptable carrier, pharmaceutically acceptable amounts of human insulin, human C-peptide, and human proinsulin, said human C-peptide being present in a ratio on a molar basis, human insulin to human C-peptide, of from about 1:4 to about 4:1, and said human proinsulin being present in a ratio on a weight basis, human insulin to human proinsulin, of from about 1:100 to about 100:1.
Claim 3
Dependent Claim
22 words
Method of claim 1, in which the molar ratio of human insulin to human C-peptide is from about 1:2 to about 2:1.
Claim 4
Dependent Claim
22 words
Method of claim 1, in which the molar ratio of human insulin to human C-peptide is from about 1:1 to about 2:1.
Claim 5
Dependent Claim
22 words
Method of claim 1, in which the weight ratio of human insulin to human proinsulin is from about 1:10 to about 100:1.
Claim 6
Dependent Claim
22 words
Method of claim 4, in which the weight ratio of human insulin to human proinsulin is from about 1:2 to about 100:1.
Claim 7
Dependent Claim
22 words
Method of claim 4, in which the weight ratio of human insulin to human proinsulin is from about 1:1 to about 20:1.
Claim 8
Dependent Claim
22 words
Method of claim 4, in which the weight ratio of human insulin to human proinsulin is from about 4:1 to about 20:1.
Claim 9
Dependent Claim
22 words
Method of claim 7, in which the molar ratio of human insulin to human C-peptide is from about 1:1 to about 2:1.
Claim 10
Dependent Claim
22 words
Method of claim 1, in which the weight ratio of human insulin to human proinsulin is from about 1:30 to about 100:1.
Claim 11
Dependent Claim
22 words
Method of claim 1, in which the weight ratio of human insulin to human proinsulin is from about 1:15 to about 100:1.
Claim 12
Dependent Claim
22 words
Method of claim 1, in which the weight ratio of human insulin to human proinsulin is from about 1:30 to about 20:1.
Claim 13
Dependent Claim
22 words
Method of claim 1, in which the weight ratio of human insulin to human proinsulin is from about 1:15 to about 20:1.
Claim 14
Dependent Claim
22 words
Method of claim 1, in which the weight ratio of human insulin to human proinsulin is from about 1:10 to about 20:1.
Claim 15
Dependent Claim
22 words
Method of claim 1, in which the weight ratio of human insulin to human proinsulin is from about 1:100 to about 1:1.
Claim 16
Dependent Claim
22 words
Method of claim 1, in which the weight ratio of human insulin to human proinsulin is from about 1:30 to about 1:1.
Claim 17
Dependent Claim
22 words
Method of claim 1, in which the weight ratio of human insulin to human proinsulin is from about 1:30 to about 1:10.
Claim 18
Dependent Claim
22 words
Method of claim 1, in which the weight ratio of human insulin to human proinsulin is from about 1:10 to about 1:1.
References Cited (Backward Citations)
US3868358A
Cited
GB2104381A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-03-23 | 1990-09-22 | 1991-03-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-03-23 | 1994-09-22 | 1995-03-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-03-23 | 1998-09-22 | 1999-03-24 | $7700.00 | Window Closed / Lapsed |